ArticlePulmonary circulation2025

Exploring Providers' Behaviors, Attitudes, and Preferences on the Treatment of Pulmonary Arterial Hypertension With Endothelin Receptor Antagonist (ERA) + Phosphodiesterase-5 Inhibitors (PDE5i).

Nicholas A Kolaitis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.